羟考酮联合回生口服液治疗晚期复发卵巢癌的临床分析

Clinical effect analysis of oxycodone combined with Hui-sheng oral liquid in treatment of advanced recurrent ovarian cancer

目的探讨盐酸羟考酮缓释片联合回生口服液治疗晚期复发卵巢癌的临床效果。方法将72例晚期复发卵巢癌患者随机分为两组,各36例,对照组入组后即给予盐酸羟考酮缓释片止痛治疗和对症治疗;联合组除接受与对照组相同的治疗外,加用回生口服液治疗。两组均持续治疗12 w,比较两组的临床疗效。结果治疗后1 w,联合组的止痛效果明显优于对照组(P<0.05);治疗后12 w,联合组的PS评分和血清CA-125及CEA水平均低于对照组(P<0.05),而中位生存时间长于对照组(P<0.05),且不良反应发生率低于对照组(P<0.05)。结论羟考酮缓释片联合回生口服液能更有效地控制晚期复发卵巢癌患者的疼痛,提高治疗效果,延长患者的生存时间,且回生口服液能够减轻羟考酮的不良反应。

Objective To explore the clinical effects of Oxycodone Hydrochloride Prolonged-release Tablets combined with Hui-sheng oral liquid in the treatment of advanced recurrent ovarian cancer. Methods A total of 72 patients with advanced recurrent ovarian cancer were randomly divided into two groups（n =36, respectively）. The control group was treated with Oxycodone Hydrochloride Prolonged-release Tablets for pain relief and symptomatic treatment, and on the basis of this, the combination group was additionally given Hui-sheng oral liquid. The two groups were treated for more than 12 W, and the clinical efficacy between the two groups was compared. Results After one week of treatment, the analgesic effect of the combination group was significantly better than that of the control group（P〈0.05）; after 12 W of treatment, the PS scores and the serum CA-125 and CEA levels were lower than those in the control group（P〈0.05）, while the median survival time was longer than that of the control group（P〈0.05） and the incidence of adverse reactions was lower than that of the control group（P〈0.05）. Conclusion Oxycodone Hydrochloride Prolongedrelease Tablets combined with Hui-sheng oral liquid can effectively control the pain of patients with advanced recurrent ovarian cancer, improve the therapeutic effect and prolong the survival time of the patients; besides, Hui-sheng oral liquid can reduce the adverse reaction of oxycodone.